

12th Asia Oncology Phase I Trials Conference (A-TOPIC) April 11 - 12, 2026, Taipei, Taiwan

April 11, 2026	Topic	Speaker	Moderator
08:30 - 08:45AM	Registration for First Session		
08:45 - 09:00AM	Opening Remark	James Chih-Hsin Yang National Taiwan University, Taipei, Taiwan Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	
09:00 - 09:30AM	The Journey of Targeting the DNA Damage Response	Ruth Plummer Newcastle University, Newcastle upon Tyne, United Kingdom	James Chih-Hsin Yang National Taiwan University, Taipei, Taiwan
09:30 - 10:00AM	Integrating Patient-Reported Outcomes into Early-Phase Oncology Trials	Christina Yap The Institute of Cancer Research, London, United Kingdom	Chiun Hsu National Taiwan University, Taipei, Taiwan
10:00 - 10:15AM	Pharmaceutical Company Pipeline: Nuvalent	Viola W. Zhu Nuvalent, Cambridge, MA, USA	Jin-Yuan Shih National Taiwan University Hospital, Taipei, Taiwan
10:15 - 10:30AM	Pharmaceutical Company Pipeline: BlossomHill Therapeutics	Alena Zalutskaya BlossomHill Therapeutics, San Diego, CA, USA	Jin-Yuan Shih National Taiwan University Hospital, Taipei, Taiwan
10:30 - 10:45AM	Coffee Break		
10:45 - 11:15AM	Exploring Novel Antigens for ADCs: TA-MUC1 as an Example	Noboru Yamamoto National Cancer Center Hospital, Tokyo, Japan	Gee-Chen Chang Chung Shan Medical University, Taichung, Taiwan
11:15 - 11:45AM	Targeting MET- and KRAS-Amplified Tumors	Yasutoshi Kuboki National Cancer Center Hospital East, Kashiwa, Chiba, Japan	Li-Yuan Bai China Medical University Hospital, Taichung, Taiwan
11:45 - 12:00PM	Pharmaceutical Company Pipeline: AbbVie	David I. Quinn AbbVie, South San Francisco, CA, USA	Ying-Chun Shen National Taiwan University Cancer Center, Taipei, Taiwan
12:00 - 12:15PM	Pharmaceutical Company Pipeline: Coherus Oncology	Anne Uyei Coherus Oncology, Redwood City, CA, USA	Ying-Chun Shen National Taiwan University Cancer Center, Taipei, Taiwan
12:15 - 01:30PM	Lunch Break		
01:30 - 02:00PM	Optimal Dose and Schedule for Immune Checkpoint Inhibitors	Li-Tzong Chen Kaohsiung Medical University, Kaohsiung, Taiwan	Kun-Huei Yeh National Taiwan University Hospital, Taipei, Taiwan
02:00 - 02:30PM	Clinical Development of T-cell Engagers in Solid Tumours	Ben Tran Peter MacCallum Cancer Centre, Melbourne, Australia	Tom Wei-Wu Chen National Taiwan University Hospital, Taipei, Taiwan
02:30 - 03:00PM	Bispecific Antibodies Targeting Dual Immune Checkpoints	Pei-Jye Voon Hospital Umum Sarawak, Kuching, Sarawak, Malaysia	Tom Wei-Wu Chen National Taiwan University Hospital, Taipei, Taiwan
03:00 - 03:15PM	Pharmaceutical Company Pipeline: Amgen	Kopei Chang Amgen Taiwan, Taipei, Taiwan	Tsung-Che (Nathan) Wu National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan
03:15 - 03:30PM	Pharmaceutical Company Pipeline: BioNTech	Chih-Yi Hsieh BioNTech, Shanghai, China	Tsung-Che (Nathan) Wu National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan
03:30 - 03:45PM	Pharmaceutical Company Pipeline: Takeda	Akiko Kimura Takeda, Osaka, Japan	Tsung-Che (Nathan) Wu National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan
03:45 - 04:00PM	Coffee Break		
04:00 - 04:30PM	Japan-Taiwan Collaboration in Drug Development: Lessons from NIR-PIT and Next-Generation Antibodies	Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	Ann-Lii Cheng National Taiwan University Cancer Center, Taipei, Taiwan
04:30 - 05:00PM	Drug Development for Squamous Cell Carcinoma of the Head and Neck: Beyond EGFR and Checkpoint Blockade	Darren Wan-Teck Lim National Cancer Centre Singapore, Singapore	Muh-Hwa Yang National Yang Ming Chiao Tung University, Taipei, Taiwan
05:00 - 05:30PM	Mechanisms of Resistance to ADCs and Therapeutic Strategies for Overcoming Resistance	Hidetoshi Hayashi Kindai University Faculty of Medicine, Osaka, Japan	Wen-Cheng Chang Chang Gung Memorial Hospital, Taoyuan, Taiwan

12th Asia Oncology Phase I Trials Conference (A-TOPIC) April 11 - 12, 2026, Taipei, Taiwan

April 12, 2026	Topic	Speaker	Moderator
08:00 - 08:15AM	Registration for Second Session		
08:15 - 08:45AM	HER2-Targeted Therapies Beyond Breast Cancer	Do-Youn Oh Seoul National University Hospital, Seoul, South Korea	Yi-Hsin Liang National Taiwan University Hospital, Taipei, Taiwan
08:45 - 09:15AM	Clinical Development of TROP2 ADC	Toshio Shimizu Kansai Medical University Hospital, Osaka, Japan	Yen-Shen Lu National Taiwan University Hospital, Taipei, Taiwan
09:15 - 09:45AM	Competing Targets, Competing Trials A Panel Discussion on Prioritizing Phase I Oncology Trials	Case Presenters: Hsin-Tuan Huang Shu-Cheng Wu Panelists: Ruth Plummer Yasutoshi Kuboki	Tom Wei-Wu Chen National Taiwan University Hospital, Taipei, Taiwan
09:45 - 10:15AM	Evolving Phase I Oncology Trials in the Precision Medicine Era in National Cancer Center Japan Hospital	Yuki Katsuya National Cancer Center Hospital, Tokyo, Japan	Wen-Pin Su National Cheng Kung University Hospital, Tainan, Taiwan
10:15 - 10:30AM	Coffee Break		
10:30 - 10:45AM	Pharmaceutical Company Pipeline: Daiichi Sankyo	Greg S. Nowakowski Daiichi Sankyo, Basking Ridge, NJ, USA	Ching-Hung Lin National Taiwan University Cancer Center, Taipei, Taiwan
10:45 - 11:00AM	Pharmaceutical Company Pipeline: Pfizer	Harald A. Weber Pfizer, Zug, Switzerland	Ching-Hung Lin National Taiwan University Cancer Center, Taipei, Taiwan
11:00 - 11:30AM	Development of RAS Inhibitors	Tsung-Che (Nathan) Wu National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan	Jih-Hsiang Lee National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan
11:30 - 11:45AM	Pharmaceutical Company Pipeline: Novartis	Igor Rakovic Novartis, Basel, Switzerland	Mei-Fang Cheng National Taiwan University Hospital, Taipei, Taiwan
11:45 - 12:00PM	Pharmaceutical Company Pipeline: Revolution Medicines	Peter Lam Revolution Medicines, Redwood City, CA, USA	Chia-Chi (Josh) Lin National Taiwan University Hospital, Taipei, Taiwan
12:00 - 12:15PM	Closing Remark	James Chih-Hsin Yang National Taiwan University, Taipei, Taiwan Toshihiko Doi National Cancer Center Hospital East, Kashiwa, Chiba, Japan	